ArciTect™ Human CRISPR Optimization Kit
Complete kit for optimization of genome editing in human cells
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
This kit has been tested and validated for use with the ArciTect™ line of genome editing products. By targeting the B2M gene that encodes a ubiquitously expressed cell-surface protein, editing efficiency can be rapidly and quantitatively assessed using flow cytometry methods. This technique also enables additional evaluation of editing success such as viability monitoring and/or assessment of cell type-specific marker expression.
Figure 1. ArciTect™ Human CRISPR Optimization Kit Exhibits High Editing Efficiency in hPSCs, T Cells, and CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs)
Cells were electroporated with RNP complexes containing sgRNA targeting B2M complexed with ArciTect™ Cas9 Nuclease protein. The cells were cultured for 72 hours following electroporation and editing efficiency was monitored by flow cytometry to detect loss of B2M expression; n = 3 biological replicates (WLS-1C iPSCs/hPSCs) or n = 3 donors (T cells and CD34+ HSPCs). No EP: non-electroporated controls.
Figure 2. Anti-Human Beta-2-Microglobulin, Clone #35 Conjugates Exhibit Equivalent Performance Across Samples to Monitor B2M Knockout Efficiency Using the ArciTect™ Human CRISPR Optimization Kit
CD34+ HSPCs isolated from two independent donors were electroporated with RNP complexes containing sgRNA targeting B2M complexed with ArciTect™ Cas9 Nuclease protein. The cells were cultured for 96 hours following electroporation and editing efficiency was monitored by flow cytometry to detect loss of B2M expression using anti-human beta-2-microglobulin, clone #35, (A, B) APC-conjugated, (C, D) FITC-conjugated, and (E, F) PE-conjugated. The histograms were derived from gated events of viable (7-AAD-negative) cells. Orange histograms: RNP-electroporated samples; grey histograms: non-electroporated control samples.
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (6)
Item added to your cart
ArciTect™ Human CRISPR Optimization Kit
The purchase of the ArciTect™ products conveys to the purchaser the limited, non-transferable right to use, in accordance with all applicable laws and regulations, the ArciTect™ products and any related material solely for research purposes only, not for any clinical, human, agricultural, veterinary, livestock, or commercial purpose, with no warranty (express or implied) from the owners or assignees of the Patents or STEMCELL Technologies each of whom expressly disclaim any warranty regarding results obtained through the use of the ArciTect™ products, and without any exception the owners or assignees of the Patents or STEMCELL Technologies, or as applicable a director, trustee, officer, employee, agent, faculty, official investigator or student thereof, will not suffer or be exposed to any liability, damages, loss, or expense of any kind whatsoever arising from or related to the use of the ArciTect™ products by a purchaser of same. Distribution of ArciTect™ products by STEMCELL Technologies is covered under at least US 8,697,359, US 8,771,945, US 8,795,965, US 8,865,406, US 8,871,445, US 8,889,356, US 8,889,418, US 8,895,308, US 8,906,616 and foreign equivalents (“Patents”).
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.